Literature DB >> 31769569

Successful treatment of fulminant Clostridioides difficile infection with emergent fecal microbiota transplantation in a patient with acute myeloid leukemia and prolonged, severe neutropenia.

Matthew S L Lee1,2, Bharat Ramakrishna3, Alan C Moss2,4, Howard S Gold1,2, Westyn Branch-Elliman2,5.   

Abstract

We present a patient with acute myeloid leukemia and prolonged, severe neutropenia who developed fulminant Clostridioides difficile infection refractory to medical therapy and was high-risk for surgical intervention. He was treated with fecal microbiota transplantation (FMT) for life-saving cure. The patient had subsequent clinical improvement, however, developed multidrug-resistant Pseudomonas aeruginosa bacteremia 2 days post-procedure. We describe subsequent investigation of this event that found this bacteremia was not related to the donor stool administered during FMT. This case adds to the literature that FMT could be considered in heavily immunocompromised patients with fulminant Clostridioides difficile infection where maximal medical therapy has been ineffective and surgery may carry an excessively high mortality risk.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Clostridioides difficile infection; fecal microbiota transplantation; immunocompromised

Mesh:

Substances:

Year:  2019        PMID: 31769569     DOI: 10.1111/tid.13216

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  2 in total

Review 1.  Fecal Microbial Transplantation in Critically Ill Patients-Structured Review and Perspectives.

Authors:  Ivana Cibulková; Veronika Řehořová; Jan Hajer; František Duška
Journal:  Biomolecules       Date:  2021-10-04

2.  Profiling of gut microbial dysbiosis in adults with myeloid leukemia.

Authors:  Dandan Yu; Xiaomin Yu; Aifang Ye; Chunquan Xu; Xiaolong Li; Wujun Geng; Liqing Zhu
Journal:  FEBS Open Bio       Date:  2021-06-24       Impact factor: 2.693

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.